The overall goals of the Protocol Specific Research Support are to promote the conduct of novel therapeutic trials by Cancer Center Faculty and to provide research nursing and data management support for high priority Cancer Center investigator-initiated clinical trials that lack extramural support. The Core grant institutional clinical trials support represents an essential funding mechanism for investigator-initiated translational research efforts. Protocol Specific Research Support from the Core grant is critical to development of clinical research and provides funding in multiple situations including early in the development of a concept when preliminary data may be required to obtain extramural peer reviewed funding and initiation of lines of investigation regarded as 'high risk' by other mechanisms. When protocols written by Cancer Center members are submitted to the Protocol Review and Monitoring System (PRMS) Committee, the investigator has the option to request Core grant support if he/she does not have a source of funds to provide nursing and data management and he/she feels that the trial has high scientific merit. Prior to the PRMS Committee meeting, the Chairman of the Committee confirms the absence of nursing/data management support from the Clinical Protocol and Data Management (CPDM) Facility administrator; the committee review includes a committee recommendation on Core grant support to the Center Director. The criteria used include high scientific merit (<2.0 on a 1-5 scoring system), translational nature of the study and a priority area of the Cancer Center's PRMS Committee review. The final approval on such trials rests with the Center Director. Since the last funding period 14 studies have received funding through this mechanism and these studies have accrued 325 patients (4 year total). This total accrual and accrual/year (81) has exceeded our target by 33% (60 accruals/year). During the next funding period, we will continue to expand our investigator-initiated clinical trials program. With the impressive portfolio of current and completed investigator-initiated trials and our increased number of clinical investigators we expect these investigators will continue to require support from the Core grant to initiate new trials and enhance their ability to compete for extramural funds. Collaboration of clinical investigators with our micro-array laboratory, pharmacology/pharmacokinetics laboratory, imaging resources and pre-clinical scientists will enhance our ability to undertake translational studies with meaningful biologic endpoints. The Hematology-Oncology Unit in The Kirklin Clinic is being expanded from 8,000 to 13,000 ft2. Included is the new outpatient research facility, with its disease-specific and phase I research clinics and will be operational in July 2004.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013148-34
Application #
7102536
Study Section
Subcommittee G - Education (NCI)
Project Start
2005-04-28
Project End
2010-03-31
Budget Start
2005-04-28
Budget End
2006-03-31
Support Year
34
Fiscal Year
2005
Total Cost
$199,244
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Geng, Mengxin; Austin, Frank; Shin, Ronald et al. (2018) Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Appl Environ Microbiol 84:
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Powell, T Clark; Dilley, Sarah E; Bae, Sejong et al. (2018) The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. J Low Genit Tract Dis 22:269-273
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230

Showing the most recent 10 out of 747 publications